Yuhao Su

No. 55, South Renmin Road
Chengdu, 610041, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

An oxidative stress - and immunotherapy-related six-gene signature defines immune subtypes and predicts prognosis and immunotherapy response in hepatocellular carcinoma.

An oxidative stress - and immunotherapy-related six-gene signature defines immune subtypes and predicts prognosis and immunotherapy response in hepatocellular carcinoma.

Journal: Gene

Published: May 22, 2026

Tumor-Associated Macrophages in Hepatocellular Carcinoma: From Ontogeny and Heterogeneity to Immune Evasion and Therapeutic Targeting.

Tumor-Associated Macrophages in Hepatocellular Carcinoma: From Ontogeny and Heterogeneity to Immune Evasion and Therapeutic Targeting.

Journal: Journal of hepatocellular carcinoma

Published: April 11, 2026

S-propargyl-cysteine remodels the HCC microenvironment and potentiates anti-PD-1 therapy through CSE/H2S-linked vascular and immune reprogramming.

S-propargyl-cysteine remodels the HCC microenvironment and potentiates anti-PD-1 therapy through CSE/H2S-linked vascular and immune reprogramming.

Journal: Journal of translational medicine

Published: February 26, 2026

Hepatitis B virus infection and outcomes of TACE plus lenvatinib and PD-1 inhibitor therapy in unresectable hepatocellular carcinoma: a real-world propensity score-matched study.

Hepatitis B virus infection and outcomes of TACE plus lenvatinib and PD-1 inhibitor therapy in unresectable hepatocellular carcinoma: a real-world propensity score-matched study.

Journal: Frontiers in immunology

Published: February 11, 2026

Prognostic Value of the Ratio of Interleukin-2 and Interleukin-10 in Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Therapy.

Prognostic Value of the Ratio of Interleukin-2 and Interleukin-10 in Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Therapy.

Journal: Technology in cancer research & treatment

Published: February 05, 2026

TACE plus lenvatinib and envafolimab for conversion therapy in unresectable HCC: a prospective pilot study.

TACE plus lenvatinib and envafolimab for conversion therapy in unresectable HCC: a prospective pilot study.

Journal: Frontiers in immunology

Published: February 02, 2026

From a Multi-Omics Signature to a Therapeutic Candidate: Computational Prediction and Experimental Validation in Liver Fibrosis.

From a Multi-Omics Signature to a Therapeutic Candidate: Computational Prediction and Experimental Validation in Liver Fibrosis.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: January 24, 2026

Development and validation of a nomogram to predict surgical resection after conversion therapy in unresectable hepatocellular carcinoma.

Development and validation of a nomogram to predict surgical resection after conversion therapy in unresectable hepatocellular carcinoma.

Journal: European journal of radiology

Published: November 13, 2025

Integrative multi-omics reveal a CD4⁺ T cell-derived six-gene signature linking the immune-stromal ecosystem to prognosis and immunotherapy selection in pancreatic cancer.

Integrative multi-omics reveal a CD4⁺ T cell-derived six-gene signature linking the immune-stromal ecosystem to prognosis and immunotherapy selection in pancreatic cancer.

Journal: BMC cancer

Published: November 03, 2025

Neoadjuvant radiotherapy for resectable hepatocellular carcinoma with vascular invasion: A systematic review and meta-analysis.

Neoadjuvant radiotherapy for resectable hepatocellular carcinoma with vascular invasion: A systematic review and meta-analysis.

Journal: Oncology letters

Published: September 25, 2025

Dendritic cell-related gene signature in pancreatic cancer stratifies patient subtypes and implicates a KCTD14-TNF signaling axis.

Dendritic cell-related gene signature in pancreatic cancer stratifies patient subtypes and implicates a KCTD14-TNF signaling axis.

Journal: Frontiers in immunology

Published: July 14, 2025

Preoperative TACE with PD-1 inhibitors and TKIs in beyond "up-to-seven" hepatocellular carcinoma: a propensity score matched analysis.

Preoperative TACE with PD-1 inhibitors and TKIs in beyond "up-to-seven" hepatocellular carcinoma: a propensity score matched analysis.

Journal: Frontiers in immunology

Published: July 01, 2025

Showing 1-12 of 22

Last Updated: 09/26/2026